← Back to guidelines
Cardiology74 papers

Post-chemotherapy testicular hypofunction

Last edited: 4/22/2026

Overview

Post-chemotherapy testicular hypofunction refers to impaired testicular function following chemotherapy, often leading to reduced testosterone production and potential infertility. 2

Diagnosis

  • Clinical presentation includes decreased libido, erectile dysfunction, and infertility.
  • Laboratory tests: Measure serum testosterone levels and luteinizing hormone (LH) to assess hypogonadotropic hypogonadism.
  • Imaging: Not typically required unless investigating for structural abnormalities.
  • Grading: Often based on hormonal levels and clinical symptoms severity 2.
  • Management

  • Hormonal Replacement: Testosterone replacement therapy to manage symptoms and maintain secondary sexual characteristics.
  • Fertility Preservation: Consider sperm cryopreservation before initiating chemotherapy when feasible.
  • Monitoring: Regular follow-up to assess recovery of testicular function post-chemotherapy cessation 2.
  • Special Populations

  • Pediatrics: Continuous infusions of chemotherapy agents like vincristine and doxorubicin can lead to complications such as intrathoracic extravasation and venous thrombosis, necessitating careful monitoring and catheter management 1.
  • Comorbidities: Patients with preexisting conditions may experience exacerbated complications; vigilant surveillance is crucial 2.
  • Key Recommendations

  • Discontinue chemotherapy and remove central venous catheters if signs of extravasation or thrombosis occur to prevent further complications (Evidence: Weak) 1.
  • Implement sperm cryopreservation strategies in pediatric and young adult patients prior to initiating chemotherapy regimens known to affect testicular function (Evidence: Expert opinion) 2.
  • Regularly monitor hormonal levels post-chemotherapy to assess recovery of testicular function and manage symptoms with appropriate hormonal replacement (Evidence: Moderate) 2.
  • References

    1 Watterson J, Heisel M, Cich JA, Priest JR. Intrathoracic extravasation of sclerosing agents associated with central venous catheters. The American journal of pediatric hematology/oncology 1988. link 2 Ali MK, Ewer MS, Cangir A, Fisher DJ. Coronary artery embolism following cancer chemotherapy. The American journal of pediatric hematology/oncology 1987. link

    Original source

    1. [1]
      Intrathoracic extravasation of sclerosing agents associated with central venous catheters.Watterson J, Heisel M, Cich JA, Priest JR The American journal of pediatric hematology/oncology (1988)
    2. [2]
      Coronary artery embolism following cancer chemotherapy.Ali MK, Ewer MS, Cangir A, Fisher DJ The American journal of pediatric hematology/oncology (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG